b r i e f c o m m u n i c at i o n s
Typical mutations associated with HPFH include heterozygous deletions or nucleotide substitutions in regions of the extended β-globin locus that regulate transcription of HBG1 or HBG2 (ref. 1) . For example, the −175 T>C HBG1 substitution de-represses γ-globin expression by creating a binding site for the transcriptional activator TAL1 (ref. 2) . Other forms of HPFH may be associated with loss of cis elements that recruit proteins that repress HBG1 or HBG2 expression. We focused on a 13-nt deletion (−102 to −114) within the HBG1 promoter (Fig. 1a) 3 . The deleted region contains a CCAAT box and a direct repeat (DR), both of which recruit transcriptional repressor proteins [4] [5] [6] [7] [8] . In individuals heterozygous for the wild-type and 13-nt-deleted HBG1 alleles, HbF expression is pancellular (expressed in all red blood cells) and comprises approximately 30% of all Hb protein (as compared to <1% for 'normal' individuals who lack the mutation), which is potentially therapeutic for hemoglobinopathies, as patients with SCD who have this level of HbF are asymptomatic 9 . We reasoned that a DNA break induced by site-directed CRISPR-Cas9 mutagenesis followed by error-prone nonhomologous end joining (NHEJ) might recapitulate effects of the 13-nt-deleted HPFH-associated HBG1 mutation 10 . We used a lentiviral vector to express mCherry, Cas9 and two different guide RNAs (gRNAs) that target this region in the human erythroblast cell line HUDEP-2, which expresses mainly HbA 11 ( Fig. 1a) . HbF protein was undetectable in mock-infected and Cas9-only-expressing control cultures and rose to approximately 17% and 3% in cells expressing mCherry, Cas9, and either gRNA-1 or gRNA-2, respectively ( Supplementary Fig. 1a ). Cells that stained positive for HbF (referred to as F-cells) increased from 2% to 46% with expression of gRNA-1, or to 26% with expression of gRNA-2 (Fig. 1b) . The relative expression of HBG1 and HBG2 (γ-globin) mRNA as a ratio of γ-globin-and β-globin-expressing transcripts (referred to as γ/(γ + β) or %HBG1/2) was increased by expression of each gRNA; HBB (β-globin) mRNA expression was decreased by expression of gRNA-1 ( Supplementary Fig. 1b,c) . Induction of HbF expression by either of two adjacent non-overlapping gRNAs suggests that this effect is due to on-target mutations rather than to off-target mutations.
Next we used the same mCherry-Cas9-gRNA-encoding lentiviral vectors to edit peripheral blood CD34 + hematopoietic stem and progenitor cells (HSPCs) from two healthy adults. Transduced HSPCs that expressed mCherry were enriched by cell sorting and then were induced to undergo erythroid differentiation. HbF protein levels rose from approximately 5% to 20% (Fig. 1c) , and the proportion of F-cells increased from 18% to 58% in the erythroid progeny of Cas9-gRNA-1-expressing CD34 + HSPCs (Fig. 1d) ; gRNA-2 expression produced similar effects but with a lesser magnitude. Gene editing did not alter the expression of erythroid-stage-specific maturation markers ( Supplementary Fig. 2a-d) . In FACS-purified α 4 -integrin + Band3 + late basophilic erythroblasts, gRNA-1 expression led to an increase in %HBG1/2 mRNA expression from 4% to 35% and a decrease in absolute HBB mRNA levels by about 50% (Supplementary Fig. 2e,f) . Increased HBG1 and HBG2 expression with decreased HBB expression indicates reversal of the γ-globin-to-β-globin switch, which is controlled by competition of the corresponding genes for an upstream enhancer, termed the locus control region (LCR) 12 .
A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition Disorders resulting from mutations in the hemoglobin subunit beta gene (HBB; which encodes b-globin), mainly sickle cell disease (SCD) and b-thalassemia, become symptomatic postnatally as fetal g-globin expression from two paralogous genes, hemoglobin subunit gamma 1 (HBG1) and HBG2, decreases and adult b-globin expression increases, thereby shifting red blood cell (RBC) hemoglobin from the fetal (referred to as HbF or a2g2) to adult (referred to as HbA or a2b2) form. These disorders are alleviated when postnatal expression of fetal g-globin is maintained. For example, in hereditary persistence of fetal hemoglobin (HPFH), a benign genetic condition, mutations attenuate g-globin-to-b-globin switching, causing high-level HbF expression throughout life. Co-inheritance of HPFH with b-thalassemia-or SCD-associated gene mutations alleviates their clinical manifestations. Here we performed CRISPR-Cas9-mediated genome editing of human blood progenitors to mutate a 13-nt sequence that is present in the promoters of the HBG1 and HBG2 genes, thereby recapitulating a naturally occurring HPFH-associated mutation. Edited progenitors produced RBCs with increased HbF levels that were sufficient to inhibit the pathological hypoxia-induced RBC morphology found in SCD. Our findings identify a potential DNA target for genome-editingmediated therapy of b-hemoglobinopathies. 
To test potential therapeutic effects of this genome-editing approach, we edited CD34 + HSPCs from three patients with SCD (HBB genotype SS), induced erythroid differentiation and examined the RBC progeny. Deoxygenated sickle hemoglobin (HbS, α2β2) forms rigid polymers that underlie the characteristic RBC morphology and pathophysiology of SCD, whereas increased levels of HbF inhibit this process 9 . To test the effects of genome editing on HbS polymerization, we cultured SCD-associated CD34 + -cell-derived RBCs under hypoxia (2% O 2 ). Approximately 30-40% of control and gene-edited cells matured to reticulocytes, late-stage anucleate RBC precursors ( Supplementary  Fig. 3a) . Consistent with previous reports, control (mock-transduced or Cas9-only-expressing) cultures contained relatively high percentages of F-cells (~65%) 13, 14 , although 25% of the cells within the entire populations showed sickle-like morphology, presumably because HbF was either absent in those cells or expressed at insufficient levels to prevent HbS polymerization (Supplementary Fig. 3b ). In contrast, Cas9 + gRNA-1 expression increased the proportion of F-cells to 90% and reduced sickle-like morphology to 4% (Fig. 1e,f) . Thus, targeting the −102 to −114 HPFH-associated region in HSPCs from patients with SCD inhibited HbS polymerization in cultured reticulocyte progeny. Residual sickling in Cas9-and gRNA-1-expressing cultures could occur from lack of editing or from mutations that do not induce HbF expression.
CRISPR-Cas9 creates targeted double-stranded DNA breaks that are repaired via error-prone NHEJ, causing nucleotide insertions and deletions (indels). γ-globin is expressed from tandem homologous genes, HBG2 and HBG1 (Supplementary Fig. 4a ). Although the naturally occurring 13-nt HPFH-associated deletion alters HBG1, HBG2 contains an identical region that is mutated in other individuals with different HPFH-associated mutations 1, 15 . To characterize the mutations induced by the Cas9-and gRNA-1-expressing lentivirus in CD34 + HSPCs, we PCR-amplified a 431-nt region surrounding the predicted cleavage sites in HBG2 or HBG1 and deep-sequenced the products. In three biological replicate experiments, the indel incidence in all of the transduced cells was 56%, 65% and 77%, with equal mutation rates in HBG1 and HBG2 (data not shown). Approximately half of the mutations were identical to the −102 to −114 HPFH-associated deletion (data not shown). It is possible that the 13-nt deletion predominates because the Cas9 cleavage site is flanked by 8-nt tandem repeats that facilitate microhomology-mediated end joining (Fig. 2a) 16 . To identify mutations associated with γ-globin induction, we purified erythroblasts that expressed low, intermediate or high levels of HbF and analyzed the promoter regions by deep sequencing (Supplementary Fig. 4b ). In four independent experiments, the 13-nt HPFH-associated deletion was enriched in HbF high cells (P < 0.05) ( Fig. 2a and Supplementary Fig. 4c) .
Transduction of CD34 + cells with the Cas9-and gRNA-1-expressing lentivirus produced over 40 different indels smaller than 13 nt (Fig. 2a  and Supplementary Fig. 4c ), although their low individual frequencies impeded efforts to determine the effects on HbF expression. Thus, we performed clonal studies by transiently expressing gRNA-1 and Cas9 in CD34 + cells, via DNA electroporation, followed by methylcellulose culture to analyze single-cell-derived burst-forming unit-erythroid (BFU-E) colonies (Fig. 2b and Supplementary Fig. 5 ). Of 344 colonies screened from three experiments, 30 had on-target mutations, with 16 containing at least one 13-nt HPFH-associated deletion (Supplementary Fig. 5) . All of the BFU-E colonies analyzed were mosaic for HBG1 and HBG2 mutations, reflecting editing over several progenitor divisions. HBG1 and HBG2 were mutated equally. The mutation frequencies correlated moderately with %HBG1/2 mRNA levels in each colony (Fig. 2b) Fig. 5 ). We also derived HUDEP-2 cell clones after transient Cas9 and gRNA-1 expression, including three lines with small (1-4 nt) bi-allelic HBG1 and HBG2 CCAAT box mutations and strong γ-globin induction (Fig. 2c-e and Supplementary Fig. 6 ). HUDEP-2 clone 6 ( Fig. 2e) and BFU-E colony 4 ( Supplementary  Fig. 5 ) contained single-nucleotide HBG1 and HBG2 insertions that preserved the core CCAAT box element and altered the DR; increased HBG1 and HBG2 mRNA was not associated with these mutations. Simultaneous double-stranded DNA cleavage at gRNA-1 recognition sites in the HBG2 and HBG1 promoters could result in NHEJmediated joining of the two ends with loss of the intervening 5.2 kb of genomic DNA (Supplementary Fig. 7a) . Indeed, we identified this deletion in several genome-edited HUDEP-2 clones ( Supplementary  Figs. 6 and 7) . We determined the frequency of this event in transiently edited cells by using quantitative PCR (qPCR) and fluorescence in situ hybridization (FISH) (Supplementary Fig. 7a) . The 5.2-kb deletion was not detected in HUDEP-2 cells after electroporation of 2 µg of a Cas9-and gRNA-1-expressing DNA plasmid, but it occurred in approximately 20% of HBG1 and HBG2 alleles after transfection of 10 µg DNA (Supplementary Fig. 7b,c) . The deletion was not detected by qPCR in human CD34 + HSPCs that were electroporated with 10 µg of the Cas9-and gRNA-1-expressing plasmid (Supplementary Fig. 7d) . Finally, deep sequencing of CD34 + HSPCs after lentiviral delivery of Cas9-and gRNA-1-encoding sequences showed no indels in the top 15 off-target sites predicted by bioinformatic analyses (Supplementary Table 1) .
The −102 to −114 regions of HBG1 and HBG2 contain CCAAT boxes and overlapping DR elements that likely mediate postnatal γ-globin-to-β-globin switching by recruiting transcriptional repressors in a developmentally regulated manner 1, 15 . Candidate CCAATbox-binding proteins include nuclear receptor subfamily 2 group F member 2 (NR2F2; also known as COUP-TFII or NF-E3) 4, 6, 8 , nuclear factor Y (NF-Y; also known as CP-1 or CBF) 4, 5 , CCAAT displacement protein (CDP) 7, 8 and CCAAT-enhancer-binding protein (C/EBP) 7 ; the DR element binds nuclear receptor subfamily 2 group C member 1 (NR2C1; also known as TR2) and NR2C2 (also known as TR4) 17 . Although the molecular triggers of γ-globin-to-β-globin switching are not fully defined, the current study shows that disruption of the −102 to −114 HBG1 and HBG2 CCAAT box-DR regions via gene editing partially reverses the switch in adult-type erythroid cells and delineates further the cis elements involved. Notably, we show that γ-globin induction can occur via small (<13 nt) NHEJ-associated mutations caused by transient editing. These mutations are independent of microhomology-mediated end joining, which is preferentially used during S phase of the cell cycle and may not occur efficiently in hematopoietic stem cells 16 .
Genome-editing technologies to manipulate hematopoietic stem cells have fueled innovative strategies for treating β-thalassemia and SCD, including correction of the SCD-associated mutation by homologydirected DNA repair 18 , reactivation of γ-globin expression via forced promoter-LCR looping 19 or NHEJ-mediated disruption of BCL11A, which encodes a repressor of HBG1 and HBG2 transcription 20 ; however, these approaches have not been tested in patients. Here we present an additional approach in which CRISPR-Cas9-mediated disruption of an HBG1-HBG2 region recapitulates a benign human condition (HPFH) by inducing HbF expression to potentially therapeutic levels, similar to those achieved via forced DNA looping or via Cas9-and gRNA-mediated disruption of a BCL11A erythroid enhancer. Future studies are now required to optimize editing of the HBG1 and that were isolated from parental cells after electroporation with a plasmid encoding Cas9, gRNA-1 and GFP (see also d and Supplementary Fig. 6 ).
(d,e) Characterization of genome-edited HUDEP-2 clones for HbF expression (d) and %HBG1/2 mRNA levels (e, left). The HBG1 and HBG2 genotypes corresponding to each clone is shown (e, right), according to the convention used in a; all cells within each clonal population contain the indicated mutations. Squares indicate clones that contain mutations in the core CCAAT box element. Throughout, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not significant; by unpaired t-test. npg b r i e f c o m m u n i c at i o n s HBG2 CCAAT box-DR site in human hematopoietic stem cells and to minimize potentially harmful off-target mutations. Overall, our study provides proof of principle for a potential approach to treat common β-hemoglobinopathies by genome editing.
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